Aortic insufficiency medical management

WikiDoc Resources for Aortic insufficiency medical management
Articles
Most recent articles on Aortic insufficiency medical management Most cited articles on Aortic insufficiency medical management Review articles on Aortic insufficiency medical management Articles on Aortic insufficiency medical management in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Aortic insufficiency medical management Images of Aortic insufficiency medical management Photos of Aortic insufficiency medical management Podcasts & MP3s on Aortic insufficiency medical management Videos on Aortic insufficiency medical management
Evidence Based Medicine
Cochrane Collaboration on Aortic insufficiency medical management Bandolier on Aortic insufficiency medical management TRIP on Aortic insufficiency medical management
Clinical Trials
Ongoing Trials on Aortic insufficiency medical management at Clinical Trials.gov Trial results on Aortic insufficiency medical management Clinical Trials on Aortic insufficiency medical management at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Aortic insufficiency medical management NICE Guidance on Aortic insufficiency medical management NHS PRODIGY Guidance FDA on Aortic insufficiency medical management CDC on Aortic insufficiency medical management
Books
Books on Aortic insufficiency medical management
News
Aortic insufficiency medical management in the news Be alerted to news on Aortic insufficiency medical management News trends on Aortic insufficiency medical management
Commentary
Blogs on Aortic insufficiency medical management
Definitions
Definitions of Aortic insufficiency medical management
Patient Resources / Community
Patient resources on Aortic insufficiency medical management Discussion groups on Aortic insufficiency medical management Patient Handouts on Aortic insufficiency medical management Directions to Hospitals Treating Aortic insufficiency medical management Risk calculators and risk factors for Aortic insufficiency medical management
Healthcare Provider Resources
Symptoms of Aortic insufficiency medical management Causes & Risk Factors for Aortic insufficiency medical management Diagnostic studies for Aortic insufficiency medical management Treatment of Aortic insufficiency medical management
Continuing Medical Education (CME)
CME Programs on Aortic insufficiency medical management
International
Aortic insufficiency medical management en Espanol Aortic insufficiency medical management en Francais
Business
Aortic insufficiency medical management in the Marketplace Patents on Aortic insufficiency medical management
Experimental / Informatics
List of terms related to Aortic insufficiency medical management

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]; Varun Kumar, M.B.B.S.; Lakshmi Gopalakrishnan, M.B.B.S.

Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [3] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Medical therapy of chronic aortic insufficiency involves the use of vasodilators. Small trials have demonstrated a benefit from the administration of ACE inhibitors, nifedipine, sodium nitroprusside and hydralazine in improving left ventricular wall stress, ejection fraction, and left ventricular mass . The use of these vasodilators is indicated only in those individuals who suffer from hypertension in addition to aortic insufficiency. The goal in using these pharmacologic agents is to decrease the afterload so that the left ventricle is unloaded. This results in reduction in left ventricular end diastolic pressure thereby preserving the left ventricular systolic function and also benefits the patients in left ventricular failure secondary to aortic insufficiency.

Long term therapy with nifedipine and hydralazine have shown to increase left ventricular ejection fraction, reduce left ventricular end diastolic volume and reduction in left ventricular mass thereby delaying the need for valve surgery . While ACE inhibitors such as enalapril and quinapril have shown to decrease left ventricular mass and end diastolic volume but with no influence on ejection fraction

Patients with severe aortic insufficiency with normal left ventricular function are recommended to undergo surgery though there are no sufficient evidences against medical management.

Use of drugs other than vasodilators, such as digoxin, diuretics and other positive inotropic drugs for long term treatment have no supporting data. Beta blockers are relatively contraindicated since they decrease heart rate and prolong diastolic phase. There by increasing the back flow of blood from aorta. However beta blockers can be considered in patients with bicuspid aortic valve with mild aortic insufficiency and aortic root diameter of more than 40mm .

ACC/AHA guidelines for use of Vasodilator therapy in Chronic severe Aortic Insufficiency

“

Class I Vasodilator therapy is indicated for chronic therapy in patients with severe aortic insufficiency who have symptoms or left ventricular dysfunction when surgery is not recommended because of additional cardiac or noncardiac factors. Class IIa Vasodilator therapy is reasonable for short-term therapy to improve the hemodynamic profile of patients with severe heart failure symptoms and severe left ventricular dysfunction before proceeding with aortic valve replacement. Class IIb Vasodilator therapy may be considered for long-term therapy in asymptomatic patients with severe aortic insufficiency who have left ventricular dilatation but normal systolic function. Class III Vasodilator therapy is not indicated for long-term therapy in asymptomatic patients with mild to moderate aortic insufficiency and normal left ventricular systolic function. Vasodilator therapy is not indicated for long-term therapy in asymptomatic patients with left ventricular systolic dysfunction who are otherwise candidates for aortic valve replacement. Vasodilator therapy is not indicated for long-term therapy in symptomatic patients with either normal left ventricular function or mild to moderate left ventricular systolic dysfunction who are otherwise candidates for aortic valve replacement.

”

Prophylactic antibiotics prior dental procedures are not recommended for all patients with aortic insufficiency as per 2007 AHA guidelines (for infective endocarditis) unless there are other indications.

Aortic insufficiency in pregnancy

Isolated aortic insufficiency in pregnant patients can be managed with combination of diuretics and vasodilators. ACE inhibitors are contraindicated in pregnancy. Patients with signs and symptoms of left ventricular failure should be monitored throughout labor and delivery with strict attention to volume status and blood pressure.

Risk Stratification

High risk: Aortic insufficiency associated with NYHA class III to IV symptoms, Marfan syndrome or left ventricular ejection fraction of less than 40%. Such patients ideally should undergo definitive surgical therapy before pregnancy.

Low risk: Aortic insufficiency associated with NYHA class I to II symptoms. Such women generally tolerate pregnancy without complications and the natural fall in systolic blood pressure during pregnancy may be beneficial in reducing the regurgitant volume.

Aortic root dilatation in pregnant patients with Marfan syndrome are at increased risk of developing aortic dissection or rupture. Patients are at high risk if aortic root diameter is greater than 40mm with approximately 10% probability of developing aortic dissection . Women with marfan syndrome should be counseled against pregnancy. However, replacement of aortic root and ascending aorta may be considered if the aortic diameter exceeds 40 mm in women with marfan syndrome who are contemplating pregnancy.